舒巴坦-多利培南联合其他抗菌药物对鲍曼不动杆菌-醋酸钙不动杆菌复合体的体外抗菌活性。
In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complex.
机构信息
Entasis Therapeutics Inc., an affiliate of Innoviva Specialty Therapeutics, Inc., Waltham, MA, USA.
Entasis Therapeutics Inc., an affiliate of Innoviva Specialty Therapeutics, Inc., Waltham, MA, USA.
出版信息
Diagn Microbiol Infect Dis. 2024 Jul;109(3):116344. doi: 10.1016/j.diagmicrobio.2024.116344. Epub 2024 May 9.
Combinations of the β-lactam/β-lactamase inhibitor sulbactam-durlobactam and seventeen antimicrobial agents were tested against strains of Acinetobacter baumannii in checkerboard assays. Most combinations resulted in indifference with no instances of antagonism. These results suggest sulbactam-durlobactam antibacterial activity against A. baumannii is unlikely to be affected if co-dosed with other antimicrobial agents.
β-内酰胺/β-内酰胺酶抑制剂舒巴坦-多鲁巴坦与十七种抗菌药物联合在棋盘微量稀释法中对鲍曼不动杆菌菌株进行了测试。大多数组合结果为无关，没有拮抗作用的例子。这些结果表明，如果与其他抗菌药物同时使用，舒巴坦-多鲁巴坦对鲍曼不动杆菌的抗菌活性不太可能受到影响。
Zotero 插件